Market openNon-fractional

AnaptysBio/ANAB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About AnaptysBio

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Ticker

ANAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

San Diego, United States

Employees

117

AnaptysBio Metrics

BasicAdvanced
$680M
Market cap
-
P/E ratio
-$6.13
EPS
-0.31
Beta
-
Dividend rate
$680M
-0.31
11.531
11.201
681.818
685.613
-7.72%
-20.22%
-136.73%
28.884
14.4
14.4
-4.944
114.78%
26.65%
-31.44%
77.79%

What the Analysts think about AnaptysBio

Analyst Ratings

Majority rating from 11 analysts.
Buy

AnaptysBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-618.30% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$7.1M
-21.11%
Net income
-$44M
4.03%
Profit margin
-618.30%
31.87%

AnaptysBio Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.75%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$1.50
-$1.41
-$1.59
-$1.64
-
Expected
-$1.70
-$1.79
-$1.60
-$1.57
-$0.89
Surprise
-11.63%
-21.40%
-0.70%
4.75%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market openNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AnaptysBio stock?

AnaptysBio (ANAB) has a market cap of $680M as of July 05, 2024.

What is the P/E ratio for AnaptysBio stock?

The price to earnings (P/E) ratio for AnaptysBio (ANAB) stock is 0 as of July 05, 2024.

Does AnaptysBio stock pay dividends?

No, AnaptysBio (ANAB) stock does not pay dividends to its shareholders as of July 05, 2024.

When is the next AnaptysBio dividend payment date?

AnaptysBio (ANAB) stock does not pay dividends to its shareholders.

What is the beta indicator for AnaptysBio?

AnaptysBio (ANAB) has a beta rating of -0.31. This means that it has an inverse relation to market volatility.

Buy or sell AnaptysBio stock

Buy or sell AnaptysBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing